...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10.
【24h】

Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10.

机译：在侵袭性慢性自身免疫性甲状腺炎中，循环趋化因子（CXC基序）配体（CXCL）9与CXCL10相关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chemokine (CXC motif) ligand (CXCL)9 (CXCL9) has been shown to be involved in autoimmune thyroid disorders, however no data are present about CXCL9 circulating levels in chronic autoimmune thyroiditis (AT) vs controls. Serum CXCL9 (and for comparison CXCL10) has been measured in patients with AT vs normal control and nontoxic multinodular goiter, and this parameter has been related to the clinical phenotype. For this study we selected 189 consecutive patients with newly diagnosed AT, 63 euthyroid controls, 30 patients with nontoxic multinodular goiter. The three groups were similar in gender distribution and age; 26% of AT patients had subclinical hypothyroidism. Serum CXCL9 was significantly higher in AT (148+/-110 pg/mL) than in controls (71+/-34 pg/mL) or patients with multinodular goiter (87+/-35 pg/mL) (p<0.0001). Among AT patients, CXCL9 levels were significantly higher in patients older than 50 years, those with a hypoechoic ultrasonographic pattern or with hypothyroidism. Also CXCL10 was confirmed to be associated with AT, overall in presence of hypothyroidism. In a multiple linear regression model of CXCL9 (ln[pg/mL]) vs age, thyroid volume, TSH, AbTg, AbTPO, hypoechoic pattern, the presence of hypervascularity, and CXCL10 (ln[pg/mL]), only TSH and CXCL10 (ln[pg/mL]) were significantly related to serum CXCL9 levels. We show that circulating CXCL9 is increased in patients with aggressive thyroiditis and hypothyroidism. A strong relation between circulating CXCL9 and CXCL10 has been first shown, underlining the importance of a T helper 1 immune attack in the initiation of AT.
机译：趋化因子（CXC基序）配体（CXCL）9（CXCL9）已被证明与自身免疫性甲状腺疾病有关，但是与慢性对照相比，在慢性自身免疫性甲状腺炎（AT）中CXCL9循环水平尚无数据。已在AT与正常对照以及无毒的多结节性甲状腺肿患者中测量了血清CXCL9（以及用于比较的CXCL10），并且该参数与临床表型有关。在本研究中，我们选择了189例新诊断为AT的连续患者，63例甲状腺功能正常的对照，30例无毒的多结节性甲状腺肿患者。这三组在性别分布和年龄上相似。 26％的AT患者患有亚临床甲状腺功能减退症。 AT（148 +/- 110 pg / mL）的血清CXCL9显着高于对照组（71 +/- 34 pg / mL）或多结节性甲状腺肿患者（87 +/- 35 pg / mL）（p <0.0001） 。在AT患者中，CXCL9水平在50岁以上，超声回声低或甲状腺功能低下的患者中明显更高。总体上，在甲状腺功能减退的情况下，CXCL10也被证实与AT相关。在CXCL9（ln [pg / mL]）与年龄，甲状腺体积，TSH，AbTg，AbTPO，低回声模式，超血管性和CXCL10（ln [pg / mL]）的多元线性回归模型中，仅TSH和CXCL10（ln [pg / mL]）与血清CXCL9水平显着相关。我们显示，在患有侵略性甲状腺炎和甲状腺功能减退症的患者中循环CXCL9增加。循环CXCL9和CXCL10之间存在密切的关系，这突显了T辅助1免疫攻击在AT发作中的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号